A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis. [electronic resource]
Producer: 20000504Description: 1414-20 p. digitalISSN:- 0028-3878
- Adult
- Autoantibodies -- blood
- Brain -- pathology
- Dose-Response Relationship, Immunologic
- Double-Blind Method
- Female
- HLA Antigens -- immunology
- HLA-DR2 Antigen -- immunology
- Humans
- Immunotherapy
- Interferon-gamma -- metabolism
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Multiple Sclerosis, Chronic Progressive -- blood
- Myelin Basic Protein -- adverse effects
- Myelin Proteins
- Myelin-Associated Glycoprotein -- immunology
- Myelin-Oligodendrocyte Glycoprotein
- Peptide Fragments -- adverse effects
- T-Lymphocytes -- immunology
- Treatment Outcome
- Vaccines, Conjugate -- adverse effects
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.